1-pyrimidinylacetamide human leukocyte elastate inhibitors
First Claim
1. A compound of formula I (formula set out hereinbelow) wherein:
- R0 is (1-5C)alkyl;
R is hydrogen;
orR is an acyl group of formula A.X.CO- in which A.X-, taken together, is hydrogen, trifluoromethyl, 2,2,2-trifluoroethoxy, amino, methoxyamino, 2,2,2-trifluoroethylamino, RbRcN.O-, RaOCONH-, R1 SO2 NH-, RaOCO-, RbRcNCO- or RaCO-;
orR is an acyl group of formula A.X.CJ- in whichJ is oxygen or sulfur;
X is a direct bond, imino, oxy or thio; and
A is as defined below orA is tetrahydropyran-4-yl, 1-methylpiperid-4-yl, or 5-methyl-1,3-dioxacyclohex-5-ylmethyl;
orR is a sulfonyl group of formula D.W.SO2 - in which D.W-, taken together, is hydroxy, amino, di(lower alkyl)amino, 2,2,2-trifluoroethylamino, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl or trifluoromethyl;
orW is a direct bond, imino, carbonylimino, oxycarbonylimino or iminocarbonylimino; and
D is as defined below;
orR is a group G as defined below;
The group A, D or G is (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-3C)alkyl, aryl, aryl(1-3C)alkyl, heteroaryl or heteroaryl(1-3C)-alkyl wherein an aryl or heteroaryl moiety may bear one or more halogeno, nitro, methyl or trifluoromethyl groups and further wherein the group A, D or G may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, lower acyloxy, COORa, CH2 COORa, CONRbRc, CH2 CONRbRc, COO(CH2)2 NReRf, cyano, SO2 R1, CONRdSO2 R1, NReRf, NRgCHO, NRgCOR2, NRgCOOR2, NRhCQNRiRj, NRkSO2 R3, SO2 NRlRm, SO2 NRnCOR4 and P(O)(ORa)2 in whichQ is oxygen or sulfur;
Ra-Rn are independently hydrogen, benzyl or lower alkyl;
or, independently, a group NRbRc, NReRf, NRiRj or NRlRm is a cyclic radical selected from a group consisting of 1-pyrrolidinyl, piperidino, morpholino or 1-piperazinyl which may bear a lower alkyl substituent at the 4-position;
or independently, a group NReRf is a cyclic radical selected from a group consisting of 2-pyrrolidinon-1-yl, succinimido, oxazolidin-2-on-3-yl, 2-benzoxazolinon-3-yl, phthalimido and cis-hexahydrophthalimido; and
R1 -R4 are independently trifluoromethyl, (1-6C)alkyl, (3-6C)cycloalkyl, aryl or heteroaryl in which the aryl or heteroaryl may bear one or more substituents selected from a group consisting of lower alkyl, hydroxy, lower alkoxy, halogeno or trifluoromethyl;
R6 is (1-5C)alkyl which has no tertiary carbon, (3-7C)cycloalkyl, aryl or heteroaryl, which aryl or heteroaryl independently may bear one or more of the substituents defined for the group A or an aryl or heteroaryl moiety thereof;
RA is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloakyl(1-3C)alkyl, aryl(1-3C)alkyl, or heteroaryl(1-3C)alkyl, wherein an aryl or heteroaryl may bear one or more halogeno, methyl or trifluoromethyl group and further wherein the group RA may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, COORs, CONRtRu, SO2 Rv, CONHSO2 Rv, NRtRu, NRsCHO, NRsCORv, NRsCOORv, NRsCONRtRu, NRsSO2 Rv, SO2 NRtRu, SO2 NRsCORv, and P(O)(ORv)2 in which Rs-Ru are independently hydrogen, benzyl or lower alkyl, or, independently, a group NRtRu is a cyclic radical selected from a group consisting of 1-pyrrolidinyl, piperidino, morpholino or 1-piperazinyl which may bear a lower alkyl group at the 4-position; and
Rv is trifluoromethyl, (1-6C)alkyl, (3-6C)cycloalkyl, aryl or heteroaryl in which the aryl or heteroaryl may bear one or more substituents selected from a group consisting of lower alkyl, hydroxy, lower alkoxy, halogeno or trifluoromethyl; and
provided that no sp3 carbon is bonded to more than one nitrogen or oxygen, except as part of a cyclic ketal or where the nitrogen bears a carbonyl group;
or,for a compound of formula I which is acidic or basic, a pharmaceutically acceptable salt thereof.
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to certain novel substituted ketones which are 1-pyrimidinylacetamide derivatives of formula I, ##STR1## set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates ##STR2## useful in the synthesis of these substituted ketones processes for preparing the substituted ketones pharmaceutical compositions containing such substituted ketones and methods for their use.
62 Citations
11 Claims
-
1. A compound of formula I (formula set out hereinbelow) wherein:
-
R0 is (1-5C)alkyl; R is hydrogen;
orR is an acyl group of formula A.X.CO- in which A.X-, taken together, is hydrogen, trifluoromethyl, 2,2,2-trifluoroethoxy, amino, methoxyamino, 2,2,2-trifluoroethylamino, RbRcN.O-, RaOCONH-, R1 SO2 NH-, RaOCO-, RbRcNCO- or RaCO-;
orR is an acyl group of formula A.X.CJ- in which J is oxygen or sulfur; X is a direct bond, imino, oxy or thio; and A is as defined below or A is tetrahydropyran-4-yl, 1-methylpiperid-4-yl, or 5-methyl-1,3-dioxacyclohex-5-ylmethyl;
orR is a sulfonyl group of formula D.W.SO2 - in which D.W-, taken together, is hydroxy, amino, di(lower alkyl)amino, 2,2,2-trifluoroethylamino, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl or trifluoromethyl;
orW is a direct bond, imino, carbonylimino, oxycarbonylimino or iminocarbonylimino; and D is as defined below;
orR is a group G as defined below; The group A, D or G is (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-3C)alkyl, aryl, aryl(1-3C)alkyl, heteroaryl or heteroaryl(1-3C)-alkyl wherein an aryl or heteroaryl moiety may bear one or more halogeno, nitro, methyl or trifluoromethyl groups and further wherein the group A, D or G may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, lower acyloxy, COORa, CH2 COORa, CONRbRc, CH2 CONRbRc, COO(CH2)2 NReRf, cyano, SO2 R1, CONRdSO2 R1, NReRf, NRgCHO, NRgCOR2, NRgCOOR2, NRhCQNRiRj, NRkSO2 R3, SO2 NRlRm, SO2 NRnCOR4 and P(O)(ORa)2 in which Q is oxygen or sulfur; Ra-Rn are independently hydrogen, benzyl or lower alkyl;
or, independently, a group NRbRc, NReRf, NRiRj or NRlRm is a cyclic radical selected from a group consisting of 1-pyrrolidinyl, piperidino, morpholino or 1-piperazinyl which may bear a lower alkyl substituent at the 4-position;
or independently, a group NReRf is a cyclic radical selected from a group consisting of 2-pyrrolidinon-1-yl, succinimido, oxazolidin-2-on-3-yl, 2-benzoxazolinon-3-yl, phthalimido and cis-hexahydrophthalimido; andR1 -R4 are independently trifluoromethyl, (1-6C)alkyl, (3-6C)cycloalkyl, aryl or heteroaryl in which the aryl or heteroaryl may bear one or more substituents selected from a group consisting of lower alkyl, hydroxy, lower alkoxy, halogeno or trifluoromethyl; R6 is (1-5C)alkyl which has no tertiary carbon, (3-7C)cycloalkyl, aryl or heteroaryl, which aryl or heteroaryl independently may bear one or more of the substituents defined for the group A or an aryl or heteroaryl moiety thereof; RA is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloakyl(1-3C)alkyl, aryl(1-3C)alkyl, or heteroaryl(1-3C)alkyl, wherein an aryl or heteroaryl may bear one or more halogeno, methyl or trifluoromethyl group and further wherein the group RA may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, COORs, CONRtRu, SO2 Rv, CONHSO2 Rv, NRtRu, NRsCHO, NRsCORv, NRsCOORv, NRsCONRtRu, NRsSO2 Rv, SO2 NRtRu, SO2 NRsCORv, and P(O)(ORv)2 in which Rs-Ru are independently hydrogen, benzyl or lower alkyl, or, independently, a group NRtRu is a cyclic radical selected from a group consisting of 1-pyrrolidinyl, piperidino, morpholino or 1-piperazinyl which may bear a lower alkyl group at the 4-position; and
Rv is trifluoromethyl, (1-6C)alkyl, (3-6C)cycloalkyl, aryl or heteroaryl in which the aryl or heteroaryl may bear one or more substituents selected from a group consisting of lower alkyl, hydroxy, lower alkoxy, halogeno or trifluoromethyl; andprovided that no sp3 carbon is bonded to more than one nitrogen or oxygen, except as part of a cyclic ketal or where the nitrogen bears a carbonyl group;
or,for a compound of formula I which is acidic or basic, a pharmaceutically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 10, 11)
-
-
9. A compound of formula Vb, set out hereinbelow, or a salt thereof ##STR4## wherein:
- R is (1-6C) alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-3C)alkyl, aryl, aryl(1-3C)alkyl, heteroaryl or heteroaryl(1-3C)-alkyl wherein an aryl or heteroaryl moiety may bear one or more halogeno, nitro, methyl or trifluoromethyl groups and further wherein the group A, D or G may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, lower acyloxy, COORa, CH2 COORa, CONRbRc, CH2 CONRbRc, COO(CH2)2 NReRf, cyano, SO2 R1, CONRdSO2 R1, NReRf, NRgCHO, NRgCOR2, NRgCOOR2, NRhCQNRiRj, NRkSO2 R3, SO2 NRlRm, SO2 NRnCOR4 and P(O)(ORa)2 in which
Q is oxygen or sulfur; Ra-Rn are independently hydrogen, benzyl or lower alkyl;
or, independently, a group NRbRc, NReRf, NRiRj or NRlRm is a cyclic radical selected from a group consisting of 1-pyrrolidinyl, piperidino, morpholino or 1-piperazinyl which may bear a lower alkyl substituent at the 4-position;
or, independently, a group NReRf is a cyclic radical selected from a group consisting of 2-pyrrolidinon-1-yl, succinimido, oxazolidin-2-on-3-yl, 2-benzoxazolinon-3-yl, phthalimido and cis-hexahydrophthalimido; andR4 -R4 are independently trifluoromethyl, (1-6C)alkyl, (3-6C)cycloalkyl, aryl or heteroaryl in which the aryl or heteroaryl may bear one or more substituents selected from a group consisting of lower alkyl, hydroxy, lower alkoxy, halogeno or trifluoromethyl; RA is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloakyl(1-3C)alkyl, aryl(1-3C)alkyl, or heteroaryl(1-3C)alkyl, wherein an aryl or heteroaryl may bear one or more halogeno, methyl or trifluoromethyl group and further wherein the group RA may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, COORs, CONRtRu, SO2 Rv, CONHSO2 Rv, NRtRu, NRsCHO, NRsCORv, NRsCOORv, NRsCONRtRu, NRsSO2 Rv, SO2 NRtRu, SO2 NRsCORv, and P(O)(ORv)2 in which Rs-Ru are independently hydrogen, benzyl or lower alkyl, or, independently, a group NRtRu is a cyclic radical selected from a group consisting of 1-pyrrolidinyl, piperidino, morpholino or 1-piperazinyl which may bear a lower alkyl group at the 4-position; and
Rv is trifluoromethyl, (1-6C)alkyl, (3-6C)cycloalkyl, aryl or heteroaryl in which the aryl or heteroaryl may bear one or more substituents selected from a group consisting of lower alkyl, hydroxy, lower alkoxy, halogeno or trifluoromethyl; andR0 is (1-5C)alkyl; R6 is (1-5C)alkyl which has no tertiary carbon, (3-7C)cycloalkyl, aryl or heteroaryl, which aryl or heteroaryl independently may bear one or more of the substituents defined for the group A or an aryl or heteroaryl moiety thereof; and Rx is a group which protects and activates a primary amino group for substitution.
- R is (1-6C) alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-3C)alkyl, aryl, aryl(1-3C)alkyl, heteroaryl or heteroaryl(1-3C)-alkyl wherein an aryl or heteroaryl moiety may bear one or more halogeno, nitro, methyl or trifluoromethyl groups and further wherein the group A, D or G may bear one or more substituents selected from a group consisting of hydroxy, lower alkoxy, lower acyloxy, COORa, CH2 COORa, CONRbRc, CH2 CONRbRc, COO(CH2)2 NReRf, cyano, SO2 R1, CONRdSO2 R1, NReRf, NRgCHO, NRgCOR2, NRgCOOR2, NRhCQNRiRj, NRkSO2 R3, SO2 NRlRm, SO2 NRnCOR4 and P(O)(ORa)2 in which
Specification